Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
CAMBRIDGE, MA—Relay Therapeutics, Inc. (NASDAQ:RLAY), a $575 million market cap biotech company whose stock has shown notable volatility this year with a 19% YTD decline, recently reported that Peter Rahmer, the company’s Chief Corporate Development Officer, sold a total of 12,103 shares of common stock in two separate transactions. The transactions, which took place on April 28 and April 30, 2025, were conducted at prices ranging from $3.00 to $3.17 per share, resulting in a total sale value of $36,540.
The first transaction involved the sale of 1,364 shares at $3.17 per share, while the second transaction saw 10,739 shares sold at $3.00 per share. These sales were executed to cover income tax withholding obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Rahmer retains direct ownership of 390,081 shares, including shares underlying RSUs. According to InvestingPro analysis, the stock is currently trading below its Fair Value, with 8 additional exclusive insights available to subscribers.
This activity was conducted in accordance with Relay Therapeutics’ policies regarding the vesting of RSUs, and Rahmer had no discretion over the sales. The company maintains a FAIR financial health score according to InvestingPro metrics, with strong liquidity as evidenced by its current ratio of 15.95.
In other recent news, Relay Therapeutics has experienced a significant adjustment in its stock target by Citizens JMP, which lowered the target from $21.00 to $12.00 while maintaining a Market Outperform rating. This change comes amid a transition from phase 2 to phase 3 trials for Relay’s drug candidate. The analyst at Citizens JMP remains optimistic, citing new pharmacokinetic and pharmacodynamic data that supports a dose reduction, potentially increasing patient tolerability. Relay Therapeutics is focusing on replacing the current treatment combination in the second-line treatment for metastatic breast cancer patients. The ReDiscover phase 2 trial results have shown promising progression-free survival improvements, with RLY-2608 achieving a 9.2-month PFS across all patients and an 11.4-month PFS in those with kinase domain mutations. The trial results suggest best-in-class efficacy and potential safety advantages for RLY-2608 in this setting. These developments are being closely monitored as Relay Therapeutics aims to set a new standard in cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.